AC Immune (ACIU) Operating Expenses (2015 - 2026)

AC Immune (ACIU) has 12 years of Operating Expenses data on file, last reported at -$20.3 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 10.3% year-over-year to -$20.3 million in Q1 2026; TTM through Mar 2026 was -$85.1 million, a 5.58% increase from a year earlier, with the FY2025 full-year figure at -$87.9 million, up 3.35% from the prior year.
• Operating Expenses for Q1 2026 stood at -$20.3 million, down from -$18.4 million in the prior quarter.
• Over the last five years, Operating Expenses for ACIU reached as high as -$17.5 million in Q3 2023 and fell as low as -$25.0 million in Q2 2025.
• Historically, Operating Expenses has averaged -$20.8 million across 5 years, with a median of -$20.6 million in 2022.
• Across the five-year window, Operating Expenses increased 21.46% in 2022 and retreated 26.27% in 2024, its largest moves.
• Year by year, Operating Expenses stood at -$19.4 million in 2022, then fell by 6.54% to -$20.7 million in 2023, then fell by 9.06% to -$22.6 million in 2024, then gained by 18.26% to -$18.4 million in 2025, then retreated by 10.21% to -$20.3 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were -$20.3 million in Q1 2026, -$18.4 million in Q4 2025, and -$21.4 million in Q3 2025.